Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications.
Marios SpanakisDanny Alon-EllenbogenPetros IoannouNikolaos SpernovasilisPublished in: Pharmacy (Basel, Switzerland) (2023)
Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug-drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary.
Keyphrases
- drug induced
- liver failure
- fatty acid
- respiratory failure
- drug administration
- healthcare
- primary care
- adverse drug
- cardiovascular disease
- aortic dissection
- type diabetes
- emergency department
- hepatitis b virus
- squamous cell carcinoma
- intensive care unit
- bone marrow
- risk assessment
- locally advanced
- electronic health record